COMMUNIQUÉS West-GlobeNewswire

WORK Medical Technology Group LTD Announces Closing of Registered Offering
22/05/2025
Hangzhou, China, May 22, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) [...]
GENFIT Reports First Quarter 2025 Financial Information
22/05/2025
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 22, 2025 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients [...]
GENFIT : Information financière du premier trimestre 2025
22/05/2025
Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 22 mai 2025 – GENFIT (Nasdaq et Euronext : GNFT) , société biopharmaceutique de stade clinique avancé engagée dans l’amélioration de la vie des [...]
Senti Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
22/05/2025
Live webcast on Thursday, May 29th at 2:40 PM ET SOUTH SAN FRANCISCO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology [...]
Inotiv, Inc. to Present at Jefferies Global Healthcare Conference 2025
22/05/2025
WEST LAFAYETTE, Ind., May 22, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and [...]
TELA Bio to Participate in the 2025 Jefferies Global Healthcare Conference
22/05/2025
MALVERN, Pa., May 22, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the [...]
Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
22/05/2025
SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced that it has commenced an [...]
Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
22/05/2025
Immix Biopharma today reported ASCO abstract results from its U.S. multi-center NEXICART-2 Phase 1/2 clinical trial of NXC-201 demonstrating strong efficacy and favorable safety. – NXC-201 demonstrated a complete [...]
Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants
22/05/2025
ISELIN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today [...]
Gyre Therapeutics’ Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China
22/05/2025
Achieved statistically significant ≥1-stage fibrosis regression at Week 52 vs. placebo (52.85% vs. 29.84%, P=0.0002). Demonstrated favorable safety and tolerability profile: 4.88% serious adverse events vs. 6.45% for [...]
UPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology
22/05/2025
LOS ANGELES, May 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has [...]
Endurance Bio Inc. Announces Selection of T-168 for Neuro-SysMed’s SLEIPNIR Platform Trial in Parkinson’s Disease
22/05/2025
SAN FRANCISCO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Endurance Bio Inc., a clinical-stage biotechnology company developing therapies for neurodegenerative and metabolic diseases, today announced that its compound, T- [...]
Houston Emerges as Global Center for Brain Health Innovation
22/05/2025
Business and policy leaders outline plans to fuel workforce development and innovation in bid to accelerate $260 billion local GDP growth potential. HOUSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Protecting and enriching [...]
Arcutis’ ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older
22/05/2025
Once-daily ZORYVE foam provides powerful clearance and rapid itch relief from head to toe with no limitation on duration of use More than half of the nearly 9 million people in the United States with plaque psoriasis [...]
Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes
22/05/2025
TEL AVIV, Israel, May 22, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“ Teva ”) announced today that it is increasing the maximum tender amount of its tender offer previously [...]
Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting
22/05/2025
WARREN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today announced that it will provide several updates to stockholders in advance of the Company’s [...]
NeurAxis Announces Closing of $5.0 Million Registered Direct Offering
22/05/2025
Strengthens Balance Sheet and Provides Growth Capital CARMEL, Ind., May 22, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing [...]
Press release: Sequana Medical announces results of Annual and Extraordinary General Meetings of Shareholders
22/05/2025
Sequana Medical announces results of Annual and Extraordinary General Meetings of Shareholders Ghent, Belgium, 22 May 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " Sequana Medical "), a [...]
FDA approves Roche’s Susvimo for diabetic retinopathy
22/05/2025
Susvimo can help people with diabetic retinopathy (DR) maintain their vision and prevent progression to blindness with only one treatment every nine months Susvimo’s innovative technology via the Port Delivery Platform [...]

Pages